A British biopharmaceutical company that makes vaccines and medicines used around the world, including the shingles shot Shingrix and the RSV vaccine Arexvy. It was formed in 2000 when Glaxo Wellcome merged with SmithKline Beecham, two giants whose roots reach back to a London pharmacy opened in 1715. The name "Glaxo" comes from "lactose" — a New Zealand firm making dried milk for babies coined it for its fortified infant food.
US FDA accepts GSK's Jemperli sBLA for priority review in dMMR/MSI-H locally advanced rectal cancer
PDUFA action date is February 2027; the application is eligible for expedited review under the National Priority Voucher program.
Show detailsHide details
FDA accepted for priority review a supplemental Biologics License Application for Jemperli (dostarlimab) in previously untreated stage II/III dMMR/MSI-H locally advanced rectal cancer.
The submission is supported by AZUR-1 trial data showing a meaningful and sustained clinical complete response rate for 12 months (cCR12).
If approved, Jemperli could eliminate the need for chemotherapy, radiation, and surgery for some patients.
The application was accepted under Project Orbis, enabling coordinated international regulatory reviews.
GSK executives acquire shares under Share Reward Plan on Aug 11, 2026
Each of the eight PDMRs acquired 14 ordinary shares (7 partnership + 7 matching) at £19.3496 per share, except Victoria Whyte who acquired 12 shares (6 partnership + 6 matching).
Show detailsHide details
On August 11, 2026, eight GSK executives and one PCA acquired ordinary shares under the company's Share Reward Plan on the London Stock Exchange.
Neil Falkingham, PCA of Lynn Baxter, also acquired 14 ordinary shares at the same price.
The transactions were initial notifications under PDMR/PCA disclosure rules.
The shares are ordinary shares of 31 ¼ pence each, ISIN GB00BN7SWP63.
GSK reports total voting rights of 4,045,411,246 as of 31 July 2026
GSK plc's issued share capital as at 31 July 2026 consisted of 4,316,292,310 ordinary shares of 31 ¼ pence each.
Show detailsHide details
Of these, 270,881,064 ordinary shares were held in Treasury.
The total number of voting rights in the Company is 4,045,411,246.
Shareholders may use this figure as the denominator for determining notification requirements under the FCA's Disclosure Guidance and Transparency Rules.
The notification was issued on 3 August 2026 and signed by Company Secretary V A Whyte.